-
Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
Cons
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 0.480% | -5.000% | 58.333% | 77.119% | 25.904% | -18.835% | -71.565% |
| Vaxart Inc. | -5.000% | 0.885% | 26.667% | 17.866% | 103.571% | -22.470% | -89.730% |
| Celldex Therapeutics | 0.780% | 4.000% | 32.653% | 33.333% | 18.182% | -36.024% | 19.266% |
News
SVP Sells Qorvo 8,226 Shares Worth $683,000
Frank P. Stewart, SVP, Advanced Cellular at Qorvo (NASDAQ:QRVO), reported the direct sale of 8,226 shares for a transaction value of approximately $683,000 on Feb. 17, 2026, according to a SEC Form
AMD CEO Lisa Su Believes Its Deal With Meta Platforms Will Be a Triple-Digit Billion Dollar Deal
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special
AMD's Multi-Billion-Dollar AI Deal: Why GPU Revenue Could Drive Steady Gains
How can Advanced Micro Devices (NASDAQ: AMD) turn AI design wins and a multi‑billion dollar GPU deal into durable revenue, despite fierce competition from competitors? Watch the video below for key


